Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Evolus (EOLS – Research Report) and Hologic (HOLX – Research Report).
Cigna (CI)
In a report issued on January 31, Whit Mayo from Leerink Partners maintained a Hold rating on Cigna. The company’s shares closed last Friday at $323.84, close to its 52-week high of $328.37.
According to TipRanks.com, Mayo is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cigna with a $359.80 average price target, a 13.9% upside from current levels. In a report issued on February 2, Wells Fargo also assigned a Hold rating to the stock.
See Insiders’ Hot Stocks on TipRanks >>
Evolus (EOLS)
In a report issued on January 31, Uy Ear from Mizuho Securities maintained a Buy rating on Evolus, with a price target of $20.00. The company’s shares closed last Friday at $13.47, close to its 52-week high of $13.74.
According to TipRanks.com, Ear is a 4-star analyst with an average return of
Evolus has an analyst consensus of Strong Buy, with a price target consensus of $22.17, representing a 71.9% upside. In a report issued on January 29, Barclays also upgraded the stock to Buy with a $16.00 price target.
Hologic (HOLX)
In a report issued on February 1, Puneet Souda from Leerink Partners maintained a Buy rating on Hologic, with a price target of $90.00. The company’s shares closed last Friday at $72.44.
According to TipRanks.com, Souda is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hologic with a $82.36 average price target, representing a 10.7% upside. In a report issued on January 23, Argus Research also maintained a Buy rating on the stock with a $89.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CI:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Cigna (NYSE:CI) Surges on Q4 Beat, Raises Dividend By 14%
- Early notable gainers among liquid option names on February 2nd
- Options Volatility and Implied Earnings Moves Today, February 02, 2024
- Cigna sees FY24 adjusted EPS at least $28.25, consensus $28.29
